FOLD News and Press, Amicus Therapeutics Inc. From 05/11/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have been through an extended lean patch, making them ideal candidates for a strong rebound. Verrica ( VRCA ): Approval of its viral skin disease treatment could transform the company into a commerci...

PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Applicat...

In a down market, you can pick up the same fundamentally robust companies at a fraction of their intrinsic value. As an orphan disease innovator, BioMarin is enjoying significant and substantial revenue increases from its approved assets. Nevertheless, the company is aggressively ...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Amicus Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

Amicus Therapeutics, Inc. (FOLD) Q1 2022 Earnings Conference Call May 09, 2022, 08:30 AM ET Company Participants Andrew Faughnan - Executive Director-Investor Relations John Crowley - Chairman and Chief Executive Officer Bradley Campbell - President and Chief Operating Officer Daphne Quimi - ...

1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold ® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparatio...

Amicus Therapeutics press release (NASDAQ:FOLD): Q1 GAAP EPS of -$0.30 misses by $0.04. Revenue of $78.7M (+18.5% Y/Y) beats by $1.56M. Cash, cash equivalents, and marketable securities totaled $411.2 million at March 31, 2022, compared to $482.5 million at December 31, 2021. Based on current...

1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold ® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparatio...

PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, 2022 at 12:00 p.m. P.T. A live audio webcast o...

Despite the bear market, Amicus Therapeutics is enjoying aggressive sales growth for its lead medicine, Galafold, for Fabry. By mid-year, you are most likely to see another approval, that is, AT-GAA for Pompe disease. As it's operating at a growth inflection point, you should pick...